Bibliometric Analysis of Global Scientific Production on COVID-19 and Vaccines
暂无分享,去创建一个
M. E. B. Moura | A. R. M. C. Valle | D. R. Freitas | A. R. B. Carvalho | Francidalma Soares Souza Carvalho Filha | Inara Viviane de Oliveira Sena | Cristiane Borges de Moura Rabêlo | Antônio Rosa de Sousa Neto | Márcia Daiane Ferreira da Silva | Marly Marques Rêgo Neta | Rosângela Nunes Almeida | Laianny Luize Lima e Silva | Girlene Ribeiro da Costa | Ivana Mayra da Silva Lira | Denise Maria Meneses Cury Portela | Amanda Tauana Oliveira e Silva
[1] S. Jeon,et al. COVID-19 Vaccination: Sociopolitical and Economic Impact in the United States , 2022, Epidemiolgia.
[2] Sun Kyong Lee,et al. Misinformation of COVID-19 vaccines and vaccine hesitancy , 2022, Scientific Reports.
[3] S. Gharbia,et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.
[4] Christina C. Chang,et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant , 2022, Cell.
[5] Christina C. Chang,et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant , 2021, medRxiv.
[6] P. Kaleebu,et al. Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts , 2021, International Journal of Infectious Diseases.
[7] A. Dehshahri,et al. A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines , 2021, International Immunopharmacology.
[8] J. Mascola,et al. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects , 2021, Immunity.
[9] R. Myers,et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.
[10] Laurin B. Weissinger,et al. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries , 2021, Nature Medicine.
[11] D. Swerdlow,et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data , 2021, The Lancet.
[12] D. Alcendor,et al. Targeting COVID-19 Vaccine Hesitancy in Minority Populations in the US: Implications for Herd Immunity , 2021, Vaccines.
[13] H. Fennema,et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.
[14] A. Arslanoğlu,et al. A 50-Year Overview of the Coronavirus Family with Science Mapping Techniques: A Review , 2021, Iranian journal of public health.
[15] Dorra Yahiaoui,et al. Entrepreneurial universities: A bibliometric analysis within the business and management domains , 2021, Technological Forecasting and Social Change.
[16] Cynthia Liu,et al. A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development , 2021, ACS central science.
[17] M. Jit,et al. COVID-19 vaccine challenges: What have we learned so far and what remains to be done? , 2021, Health Policy.
[18] S. Madhi,et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant , 2021, The New England Journal of Medicine.
[19] C. Latkin,et al. COVID-19 vaccine intentions in the United States, a social-ecological framework , 2021, Vaccine.
[20] M. Hernán,et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting , 2021, The New England journal of medicine.
[21] S. Hernández-Díaz,et al. COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries , 2021, European Journal of Epidemiology.
[22] V. Gushchin,et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia , 2021, The Lancet.
[23] M. E. B. Moura,et al. Analysis of scientific production on the new coronavirus (COVID-19): a bibliometric analysis , 2021, Sao Paulo medical journal = Revista paulista de medicina.
[24] A. Sheikh,et al. COVID-19 Vaccine Acceptance among Health Care Workers in the United States , 2021, medRxiv.
[25] Nguyen H. Tran,et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.
[26] Joe Hasell,et al. Coronavirus disease (COVID-19) , 2020, Arab Society: A Compendium of Social Statistics.
[27] Graham Lawton. Sputnik V , 2021, New Scientist.
[28] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[29] Mujeeb Khan,et al. COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far , 2020, Molecules.
[30] A. Pollard,et al. A guide to vaccinology: from basic principles to new developments , 2020, Nature reviews. Immunology.
[31] Jon Cohen. Shots of hope. , 2020, Science.
[32] L. Wong,et al. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. , 2020, PLoS neglected tropical diseases.
[33] S. Lewandowsky,et al. COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II , 2020, Psychological Medicine.
[34] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[35] M. Aria,et al. The scholar’s best friend: research trends in dog cognitive and behavioral studies , 2020, Animal Cognition.
[36] Lawrence O Gostin,et al. A global survey of potential acceptance of a COVID-19 vaccine , 2020, Nature Medicine.
[37] E. Walsh,et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.
[38] Diego Carrión-Álvarez,et al. Fake news in COVID-19: A perspective , 2020, Health promotion perspectives.
[39] R. Baric,et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults , 2020, The New England journal of medicine.
[40] Ziqin Deng,et al. Bibliometric and Visualization Analysis of Human Coronaviruses: Prospects and Implications for COVID-19 Research , 2020, Frontiers in Cellular and Infection Microbiology.
[41] S. Crawford,et al. Attitudes Toward a Potential SARS-CoV-2 Vaccine: A Survey of U.S. Adults , 2020, Annals of Internal Medicine.
[42] Jiahao Wang,et al. Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China , 2020, Vaccines.
[43] M. Pennell,et al. Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? , 2020, Vaccine.
[44] E. Walsh,et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults , 2020, Nature.
[45] A. Okoh,et al. Global research trends on bioflocculant potentials in wastewater remediation from 1990 to 2019 using a bibliometric approach , 2020, Letters in applied microbiology.
[46] L. Wong,et al. The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay , 2020, Human vaccines & immunotherapeutics.
[47] Nguyen H. Tran,et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial , 2020, The Lancet.
[48] J. Mascola,et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.
[49] R. Owens,et al. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19 , 2020, npj Vaccines.
[50] A. Dror,et al. Vaccine hesitancy: the next challenge in the fight against COVID-19 , 2020, European Journal of Epidemiology.
[51] Robert T. Chen,et al. Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines , 2020, Vaccine.
[52] Young Chan Kim,et al. COVID-19 vaccines: breaking record times to first-in-human trials , 2020, npj Vaccines.
[53] Zacharias E. Andreadakis,et al. The COVID-19 vaccine development landscape , 2020, Nature Reviews Drug Discovery.
[54] Longxiang Xie,et al. Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV , 2020, Viruses.
[55] O. Launay,et al. [History and principles of vaccination]. , 2019, Revue des maladies respiratoires.
[56] Vincent A. Traag,et al. From Louvain to Leiden: guaranteeing well-connected communities , 2018, Scientific Reports.
[57] A. Okoh,et al. A global bibliometric analysis of Plesiomonas-related research (1990 – 2017) , 2018, PloS one.
[58] O. Dada. A Model of Entrepreneurial Autonomy in Franchised Outlets: A Systematic Review of the Empirical Evidence , 2018 .
[59] Massimo Aria,et al. bibliometrix: An R-tool for comprehensive science mapping analysis , 2017, J. Informetrics.
[60] H. Larson,et al. The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations. , 2017, Vaccine.
[61] Andrea Rey-Martí,et al. A bibliometric analysis of social entrepreneurship , 2016 .
[62] X. Bosch-Capblanch,et al. Exposing concerns about vaccination in low- and middle-income countries: a systematic review , 2015, International Journal of Public Health.
[63] N. MacDonald. Vaccine hesitancy: Definition, scope and determinants. , 2015, Vaccine.
[64] Ivan Zupic,et al. Bibliometric Methods in Management and Organization , 2014 .
[65] John McCormick,et al. The Member States , 2011 .
[66] M. Huycke. Smallpox in the post-eradication era. , 2002, The Journal of the Oklahoma State Medical Association.
[67] Eugene Garfield,et al. KeyWords Plus™—algorithmic derivative indexing , 1993 .
[68] J. J. Hubert. Linguistic indicators , 1980 .
[69] R. B.,et al. The United Nations , 1947, Nature.